HealthcareJul 16, 2026

Sorrento Therapeutics

Company Profile Analysis

Book Demo Subscribe Now

Sorrento Therapeutics - Healthcare showcase

Year Founded & Workforce

1988-12-31

200 Employees

Industry

Healthcare

Services

Sorrento Therapeutics Overview

Company Headquarter: ‎ California, US

Founded: 1989

Workforce: ~200

Company Working: Sorrento Therapeutics (Sorrento) is an antibody-centric, clinical stage biopharmaceutical company that develops new treatments for cancer, inflammation, and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar antibodies, as well as clinical CAR-T therapies targeting solid tumors. It has a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB), clinical stage CAR-T, intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir).

Company Snapshot

$8.2M

Revenue

200

Employees

1988-12-31

Founded

A plan for every need

Forecast+

Get unlimited access to forecasts, charts, and company data across every research report on Wantstats.

USD200/mo

About the Author

Wantstats Research Team

Wantstats' research desk profiles Sorrento Therapeutics as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Sorrento Therapeutics

Company Headquarter: ‎ California, US Founded: 1989 Workforce: ~200 Company Working: Sorrento Therapeutics (Sorrento) is an antibody-centric, clinical stage biopharmaceutical company that develops new treatments for cancer, inflammation, and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar antibodies, as well as clinical CAR-T therapies targeting solid tumors. It has a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB), clinical stage CAR-T, intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir).

Starting from

$4,950